ERBB2 and breast carcinoma: However, both HER2-enriched and TN breast cancer subtype patients showed a significant association between pathological response to NAC and survival outcome (p = 0.043 < 0.05, and p = 0.042 < 0.05, respectively, Figures 2C,D).